Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 7/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12360887 | 1.00 | DPP4 (0.38) | DPP4CYP3A4CYP2C19CYP2C9CRHR1 | |
| SCHEMBL12360890 | 1.00 | DPP4 (0.38) | DPP4CYP3A4CYP2C19CYP2C9CRHR1 | |
| SCHEMBL1923838 | 0.91 | CRHR1 (0.38) | DPP4CYP3A4CYP2C19CYP2C9CRHR1 | |
| SCHEMBL1921789 | 0.86 | DPP4 (0.38) | DPP4CYP3A4CYP2C19CYP2C9CRHR1 | |
| SCHEMBL1922743 | 0.86 | DPP4 (0.38) | DPP4CYP3A4CYP2C19CYP2C9CRHR1 | |
| SCHEMBL1922410 | 0.83 | DPP4 (0.38) | DPP4CYP3A4CYP2C19CYP2C9CRHR1 | |
| SCHEMBL1922541 | 0.82 | CRHR1 (0.41) | DPP4CRHR1 | |
| SCHEMBL1922209 | 0.82 | DPP4 (0.37) | DPP4CYP3A4CYP2C19CYP2C9CRHR1 | |
| SCHEMBL1922550 | 0.81 | CRHR1 (0.42) | DPP4CRHR1DPP8 | |
| SCHEMBL1922024 | 0.80 | CRHR1 (0.41) | DPP4CRHR1DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011529943-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | claimed |
| EP-2328902-A1 | PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | Novartis AG (CH) | 2011-06-08 | — | — | EP | claimed |
| WO-2010015628-A1 | PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | claimed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | claimed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-2328902-A1 | PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | Novartis AG (CH) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010015628-A1 | PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015628-A1 | PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035874-A1 | Organic compounds | CRH, CRHR1, CRHR2 | DPP4 958/4885CYP3A4 1380/4885CYP2C19 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.